Yahua Group also stated that the termination of the investment is mainly based on the judgement of current international environmental, which is expected to have a greater impact on the mine development cycle.
Valneva and Pfizer initiate phase 3 Lyme disease vaccine study pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
21st Austria weekly - Valneva; AT&S 20/06/2022 [pic1]Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement updated the terms of their Collaboration License for Lyme disease candidate VLA15. As previously on April 26 2022 plans to initiate Phase 3 study VLA15 in third quarter 2022. part Agreement